The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Biontech, a Germany-based cancer immunotherapy developer spun out of Johannes Gutenberg University Mainz, has filed for a $100m initial public offering on the Nasdaq Global Select Market.
The filing comes after reports in March this year that the company would target $800m in a forthcoming IPO but it is yet to set a price range.
Biontech is working on the development of individualised immunotherapies to treat cancer and potentially other diseases.
Part of the IPO proceeds…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?